“It’s concerning when you consider [C. diff] is one of the most common infections acquired during hospital visits in the Western hemisphere, and the most likely cause of diarrhea for patients and staff in hospitals,” said researcher Ramiz Boulos, PhD, adjunct research associate at Flinders University and CEO of Boulos & Cooper Pharmaceuticals.
When researchers gave doses of the new antibiotic, called Ramizol, to hamsters infected with a lethal dose of the bacteria, a significant proportion of the hamsters survived the infection.
No rats in the study suffered serious side effects or weight changes, either.
“Our research indicates Ramizol is an extremely well-tolerated antibiotic in rats, with good microbiology and antioxidant properties. It also has high chemical stability and is scalable because of the low cost of manufacturing, which could make it a viable treatment option,” Dr. Boulos said.
The findings may pave the way for a simple C. diff treatment, but further studies are needed to pursue its development to treat humans, the researchers said.
More articles on clinical leadership and infection control:
Senators seek info on universal flu vaccine research: 4 takeaways
CDC releases updated map of investments to fight antibiotic resistance
Researchers develop AI tool for UTI detection
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.